Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL
Authors
Keywords
-
Journal
PROSTATE CANCER AND PROSTATIC DISEASES
Volume 20, Issue 2, Pages 221-227
Publisher
Springer Nature
Online
2017-01-24
DOI
10.1038/pcan.2016.71
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
- (2016) Nicholas D James et al. LANCET
- Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data
- (2016) Claire L Vale et al. LANCET ONCOLOGY
- Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer
- (2016) Himisha Beltran et al. NATURE MEDICINE
- Integrating outpatient palliative care into a metastatic breast oncology clinic.
- (2015) Rebecca Small et al. JOURNAL OF CLINICAL ONCOLOGY
- The evolutionary history of lethal metastatic prostate cancer
- (2015) Gunes Gundem et al. NATURE
- Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
- (2015) Christopher J. Sweeney et al. NEW ENGLAND JOURNAL OF MEDICINE
- Aggressive Variants of Castration-Resistant Prostate Cancer
- (2014) H. Beltran et al. CLINICAL CANCER RESEARCH
- Optimal management of metastatic castration-resistant prostate cancer: Highlights from a European Expert Consensus Panel
- (2014) John M. Fitzpatrick et al. EUROPEAN JOURNAL OF CANCER
- Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial
- (2014) Peter Hoskin et al. LANCET ONCOLOGY
- Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
- (2014) Tomasz M. Beer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer
- (2013) A. M. Aparicio et al. CLINICAL CANCER RESEARCH
- Molecular States Underlying Androgen Receptor Activation: A Framework for Therapeutics Targeting Androgen Signaling in Prostate Cancer
- (2011) Peter S. Nelson JOURNAL OF CLINICAL ONCOLOGY
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group
- (2008) Howard I. Scher et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More